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INTRODUCTION
Multiple myeloma is an incurable and heterogeneous 
plasma cell neoplasm that affects about 6.3 per 100.000 
people per year worldwide (i.e., 25.850 new cases only 
in 2015) and represents 1.6% of all cancers and 2% of 
all cancer deaths [1]. In spite of the widespread use of 
proteasome inhibitors and immunomodulatory drugs, 
which has dramatically improved the life expectancy 
of MM patients over the last few decades [2, 3], MM 
survival still remains poor with a 5-year survival of 46.6% 
(SEER Cancer Statistics Review, http://seer.cancer.gov/
csr/1975_2012/). 
Epidemiological and observational studies have 
consistently identified several factors that affect MM 
patient survival such as age at diagnosis [4, 5], stage at 
diagnosis (coded by either the Durie-Salmon staging 
system (DSS) [6] or the International Staging System 
(ISS)) [7], Eastern Cooperative Oncology Group (ECOG) 
performance status [8], renal failure [9, 10], high plasma 
cell proliferative rate [11, 12], high lactate deshydrogenase 
(LDH) levels [13] and chromosomal abnormalities 
[14–18]. Increasing evidences point towards a positive 
correlation of pre-existing type 2 diabetes (T2D) with MM 
risk [19] but also with the appearance of severe clinical 
complications [20–23] and patient survival [24, 25]. In 
this regard, Chiu et al. (2006) reported that high level of 
postload glucose was associated with increased risk of 
mortality in hematological malignancies [24] whereas 
Chou et al. (2012) reported that MM patients with pre-
existing T2D have 50% higher all-cause mortality 
compared with non-diabetic patients [25]. These 
observations might be explained, at least in part, by the 
stimulatory effects of T2D-associated hyperglycaemia, 
insulin resistance and resulting hyperinsulinemia on 
MM cell growth [26, 27] but also by the deregulation 
of tumour-suppressor genes linked to T2D (such as 
CDKN2A-2B, KCNQ1, HNF1B) [28–30] that might 
lead to uncontrolled cell proliferation, cell differentiation 
and disease progression and, consequently, to shorter 
survival periods. In support of this notion, CDKN2A-2B 
genes have been found to be frequently hypermethylated 
in MM [31–33] whereas loss of expression of KCNQ1 
has been associated with poor overall survival in cancer 
patients [34]. Furthermore, emerging evidences also 
suggest that the activation of certain T2D-related genes 
(such as NOTCH2) may induce MM cell migration from 
the infiltrated site to different bone marrow districts [35] 
and promote osteoclast formation [36], which is a process 
intimately related to proliferation and long-term survival 
of MM cells [37]. 
Although germline variants may influence the 
susceptibility of MM [38–43] and survival [39, 44–46], the 
knowledge regarding the role of diabetogenic variants in 
modulating the risk of MM and survival remains scarce. We 
have recently reported that diabetogenic variants influence 
MM risk [47] and recent genome-wide association studies 
(GWAS) have also suggested the involvement of genetic 
variants within the MTHFD1L, AKAP12 and FOPNL loci 
in determining MM patient survival [39, 44, 45] but also an 
indirect implication of diabetogenic genes such as TCF7L2 
[45]. Johnson et al. (2016) reported in their GWAS a strong 
association of rs12374648, which maps to a binding site for 
the transcription factor TCF7L2, with MM overall survival 
(OS) and proposed a functional mechanism of this variant 
to modulate the synthesis of purines and the regulation of 
cell cycle [45]. 
Based on these findings, we explored for the first 
time the relationship between diabetogenic variants 
and OS of MM patients in a study developed in the 
context of the International Multiple Myeloma rESEarch 
(IMMENSE) consortium. We attempted to confirm our 
findings by analysing GWAS data on an independent set 
of German MM patients (Heidelberg cohort) [45].
ABSTRACT
Diabetogenic single nucleotide polymorphisms (SNPs) have recently been 
associated with multiple myeloma (MM) risk but their impact on overall survival (OS) 
of MM patients has not been analysed yet. In order to investigate the impact of 58 
GWAS-identified variants for type 2 diabetes (T2D) on OS of patients with MM, we 
analysed genotyping data of 936 MM patients collected by the International Multiple 
Myeloma rESEarch (IMMENSE) consortium and an independent set of 700 MM patients 
recruited by the University Clinic of Heidelberg. A meta-analysis of the cox regression 
results of the two sets showed that rs7501939 located in the HNF1B gene negatively 
impacted OS (HRRec= 1.44, 95% CI = 1.18–1.76, P = 0.0001). The meta-analysis also 
showed a noteworthy gender-specific association of the SLC30A8rs13266634 SNP with OS. 
The presence of each additional copy of the minor allele at rs13266634 was associated 
with poor OS in men whereas no association was seen in women (HRMen-Add = 1.32, 95% 
CI 1.13–1.54, P = 0.0003). In conclusion, these data suggest that the HNF1Brs7501939 
SNP confers poor OS in patients with MM and that a SNP in SLC30A8 affect OS in men. 
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RESULTS
The demographic and clinical characteristics of the 
MM patients included in the IMMENSE (n = 939) and 
Heidelberg (n = 700) cohorts are listed in Table 1. The 
median age at diagnosis was similar in both populations 
(59.73 ± 10.08 vs. 55.85 ± 8.33) but the male/female 
ratio was higher in the Heidelberg cohort (1.36 vs. 1.06). 
Durie-Salmon stage was available for IMMENSE and 
Heidelberg cohorts and included patients at stages I, II and 
III (11.83%, 23.54% and 64.63% vs. 0.8% , 12.4% and 
86.8% , respectively). 
All SNPs tested showed genotype frequencies 
consistent with the HWE (P > 0.001) and the observed 
allele frequency for all selected SNPs was in accordance 
with Hapmap data. When we evaluated the effect of 
selected polymorphisms on MM OS in the IMMENSE 
population, we found that 6 SNPs showed a noteworthy 
association with OS. The most relevant effect was observed 
for the HNF1Brs7501939 SNP that was associated with poor 
OS when recessive and log-additive models of inheritance 
were assumed (HRREC = 1.49, 95% CI 1.11–2.00, 
P = 0.008 and HRADD = 1.34 95% CI 1.13–1.59, P = 0.001, 
respectively; Table 2). Patients harbouring the non-
diabetogenic HNF1Brs7501939T/T genotype showed a 
median survival time (MST) significantly shorter than 
those carrying the C allele (MSTT/T = 81.91 months vs. 
MSTC/C+C/T = 101.42 months; Figure 1A). This result was 
confirmed with the 700 MM patients recruited from the 
University Clinic of Heidelberg (HRREC = 1.40, 95% CI 
1.06–1.84 and MSTT/T = 74.4 months vs. MSTC/C+C/T = 97.2 
months; Table 3 and Figure 1B). The result of the meta-
analysis for this SNP remained significant after correction 
for multiple testing (HRMeta-Rec = 1.44, 95% CI 1.18–1.76, 
P = 0.0001, I2 = 0.0% , PHet = 0.74; Table 3). According to 
publicly available eQTL data for human peripheral blood 
mononuclear cells, the risk allele (T) was associated with 
higher HNF1B mRNA expression levels (Z score = 3.31, 
P = 9.23•10–4 and FDR = 0.23). However, we could not 
validate this finding using eQTL data on plasma cells 
from 665 German MM patients (P = 0.60; Supplementary 
Table S1). Nonetheless, according to Haploreg and 
ENCODE annotation data, the rs7501939 SNP resides 
near of a poised promoter in many cell lines including a 
lymphoblastoid and human stem cell lines (GM12878 and 
H1-HSCs) that might be rapidly activated upon specific 
stimuli. In addition, this SNP was predicted to change 
binding motifs for 2 regulatory transcription factors 
(CEBPB and p300) and mapped among enhancer histone 
marks in primary naïve and memory forms of cytotoxic 
T cells (CD8
+) and helper T cells (CD4
+) from peripheral 
blood.
We also observed significant associations at 
P < 0.05 for SNPs within CDKN2A-2B, GCKR, 
KCNQ1 and SLC30A8 genes with OS in the IMMENSE 
population. Thus, patients carrying the KCNQ1rs2074196T 
and SLC30A8rs13266634T alleles or the GCKRrs1260326T/T 
genotype had an increased risk of death whereas subjects 
bearing the CDKN2A-2Brs564398C/C genotype showed longer 
OS (Table 2 and Supplementary Tables S2–S4). The 
association of the SLC30A8rs13266634T allele with OS was 
confirmed in the Heidelberg population and the meta-
analysis showed that the presence of each additional 
copy of the SLC30A8rs13266634T allele was associated with 
poor OS (HRMeta-Add = 1.22, 95% CI 1.09-1.37; Table 3). 
Although the association of the SLC2A2rs11920090 SNP with 
OS was not significant in the IMMENSE population, we 
observed a significant association of this variant with 
MM survival in the Heidelberg population that remained 
significant in the pooled analysis. Patients harbouring 
the SLC2A2rs11920090T allele showed a better survival 
compared with those carrying the A/A genotype (HRMeta-
Dom = 0.80, 95% CI 0.66-0.97; Table 3). The meta-analysis 
also showed a weak association of the TCF7L2rs7903146T 
allele with better survival that was neither significant in 
the IMMENSE population nor in the Heidelberg cohort 
(HRMeta-Dom = 0.84, 95% CI 0.71–0.98). Based on Haploreg 
data, the missense rs13266634 SNP was predicted to 
change binding motifs for transcription factors implicated 
in tumorigenesis (AP1 and PAX5) and mapped on 
enhancer histone marks in several human embrionic stem 
cell lines. In addition, this polymorphism affects binding 
to 5 proteins implicated in cancer development (CCNT2, 
GATA2, TAL1, KAP1 and CTCF). On the other hand, the 
rs11920090 and rs7903146 SNPs mapped among enhancer 
and promoter histone marks in bone marrow- and/or 
adipose-derived mesenchymal stem cells. In addition, the 
rs7903146 SNP was predicted to alter the binding site of 
7 transcription factors. However, despite the consistency 
and the potential interest of these findings, none of the 
associations of the SLC2A2, SLC30A8, and TCF7L2 SNPs 
with OS remained significant after correction for multiple 
testing and, therefore, require further confirmation. Given 
the lack of genetic information in the GWAS conducted 
in the Heidelberg population for SNPs within MADD and 
KCNQ1 genes, we imputed genotypes to test whether 
the preliminary associations observed in the IMMENSE 
population could be validated. Although there was no 
imputed data available for the KCNQ1 SNP, the meta-
analysis of IMMENSE data with imputed genotypes of 
MADD variants in the Heidelberg cohort suggested a link 
between this locus and MM survival (HRMeta-Rec = 0.75, 
95% CI 0.57–0.99; Table 3). 
Based on the evidences that point toward the 
existence of gender-associated differences in survival 
for patients with MM [48], we decided to carry out 
a gender-stratified analysis. This analysis revealed 
gender-specific associations for SNPs within or near 
the ADAMTS9, KCNJ11, PROX1 and SLC30A8 genes 
with OS. We found that men carrying the KCNJ11rs5215C 
or SLC30A8rs13266634T alleles had poorer OS compared 
with those harbouring the wild type genotype whereas 
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an opposite but not significant effect was seen in 
women (PInteraction = 0.022 and PInteraction = 0.057, 
respectively; Table 2 and Supplementary Table S2–S4). 
We also observed that women carrying the PROX1rs340874G 
allele or the ADAMTS9rs4607103T/T genotype experienced a 
poorer survival with an opposite but not significant effect 
in men (PInteraction = 0.016 and PInteraction = 0.024). In order to 
confirm these gender-specific associations, we performed a 
Table 1: Clinical characteristics of IMMEnSE and Heidelberg cohorts
IMMENSE population
MM patients (n = 936)
Country of origin
Gender
M/F (Total)
Mean Age
( ± STD)
Median Age
(Range)
 Italy 69/69 (138) 61.31 ± 9.47 51.0 (35–86)
 Poland 145/163 (308) 62.48 ± 10.50 52.0 (34–86)
 Spain 49/55 (104) 62.44 ± 11.45 66.0 (22–88)
 France 42/33 (75) 55.80 ± 9.04 41.0 (34–75)
 Portugal 14/22 (36) 65.22 ± 9.54 35.0 (45–80)
 Denmark 163/112 (275) 55.18 ± 7.32 51.0 (29–69)
Demographic variables
 Age (years, average ± SD) 59.73 ± 10.08
 Sex ratio (male/female) 1.06 (482/454)
Overall survival (months) 99.69 [92.98,106.39]
 Number of deaths 323
 Median follow-up time (months) 100 (52–111)
Disease stage (Durie-Salmon)*
 Stage I   93 (11.83)
 Stage II  185 (23.54)
 Stage III   508 (64.63)
Heidelberg population
MM patients (n = 700)
Country of origin
Gender
M/F (Total)
Mean Age
( ± STD)
Median Age
(Range)
 Germany (HD3 trial) 56/42 (98) 55.42 ± 7.47 56.5 (38–65)
 Germany (HD4 trial) 170/121 (291) 55.02 ± 7.30 57.0 (27–65)
 Germany (non-trial) 178/133 (311) 56.76 ± 9.37 57.2 (24–73)
Demographic variables
 Age (years, average ± SD) 55.85 ± 8.33
 Sex ratio (male/female) 1.36 (404/296)
Overall survival (months)∂ 91.2 [85.5,105]
 Number of deaths 326
 Median follow-up time (months) 84.3 (80–88)
Disease stage (Durie-Salmon)
 Stage I 5 (0.8)
 Stage II 82 (12.4)
 Stage III 575 (86.8)
Abbreviations: IMMENSE, International Multiple Myeloma rESEarch; MM, Multiple Myeloma; SD, standard deviation.
*Durie-Salmon data was not available for 150 MM patients. 
∂Median overall survival after diagnosis (IMMENSE) or the 1st autotransplant (Heidelberg cohort) (KM estimators).
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Table 2: Association of T2D–related variants and overall survival (OS) of MM patients
OVERALL (N = 936) MEN (N = 482) WOMEN (N = 454)
Variant_
dbSNP Gene
OR  
(95% CI)a Pvalue
OR  
(95% CI)b Pvalue
OR  
(95% CI)b Pvalue PInteraction
rs2641348 ADAM30 0.94  (0.69–1.28) 0.69
0.99  
(0.67–1.48) 0.97
0.87  
(0.53–1.41) 0.56 0.70
rs4607103† ADAMTS9 1.23  (0.76–2.00) 0.40
0.83  
(0.42–1.63) 0.58
2.53  
(1.26–5.07) 0.009 0.024
rs11708067 ADCY5 0.87  (0.68–1.11) 0.25
1.02  
(0.75–1.39) 0.89
0.63  
(0.42–0.95) 0.028 0.08
rs10885122 ADRA2A 1.03  (0.79–1.33) 0.83
1.01  
(0.72–1.40) 0.97
1.07  
(0.71–1.62) 0.73 0.89
rs1552224 ARAPI, CENTD2
0.88  
(0.68–1.15) 0.35
0.90  
(0.64–1.26) 0.55
0.83  
(0.54–1.25) 0.37 0.77
rs10490072 BCL11A 1.05  (0.83–1.32) 0.70
1.22  
(0.90–1.65) 0.19
0.85  
(0.59–1.23) 0.39 0.11
rs12779790 CDC123, CAMK1D
0.86  
(0.67–1.11) 0.24
1.06  
(0.77–1.46) 0.72
0.64  
(0.43–0.97) 0.035 0.06
rs7754840 CDKAL1 1.14  (0.90–1.44) 0.27
1.22  
(0.90–1.65) 0.20
1.06  
(0.74–1.53) 0.75 0.52
rs564398† CDKN2A–2B 0.64  (0.42–0.98) 0.042
0.62  
(0.36–1.07) 0.084
0.71  
(0.34–1.47) 0.36 0.88
rs10811661 CDKN2A–2B 0.93  (0.72–1.19) 0.55
0.93  
(0.67–1.30) 0.68
0.92  
(0.63–1.35) 0.67 0.92
rs2383208 CDKN2A–2B 0.94  (0.73–1.21) 0.64
0.92  
(0.66–1.29) 0.64
0.95  
(0.65–1.41) 0.81 0.87
rs4240702 COL5A1 0.88  (0.68–1.15) 0.35
0.85  
(0.60–1.21) 0.36
0.95  
(0.63–1.44) 0.82 0.65
rs11605924 CRY2 0.91  (0.70–1.18) 0.47
0.81  
(0.58–1.14) 0.23
1.09  
(0.71–1.69) 0.68 0.29
rs1153188 DCD 1.18  (0.94–1.48) 0.16
1.25  
(0.92–1.69) 0.15
1.09  
(0.76–1.57) 0.63 0.58
rs1113132 EXT2 1.02  (0.81–1.28) 0.86
0.96  
(0.71–1.30) 0.79
1.08  
(0.75–1.56) 0.66 0.57
rs174550 FADS1 1.00  (0.79–1.26) 1.00
0.97  
(0.72–1.30) 0.82
1.05  
(0.73–1.51) 0.80 0.71
rs11071657 FAM148B 0.86  (0.68–1.09) 0.22
0.96  
(0.70–1.32) 0.81
0.77  
(0.53–1.12) 0.17 0.44
rs17044137 FLJ39370 1.06  (0.84–1.33) 0.64
1.07  
(0.79–1.44) 0.67
1.03  
(0.71–1.50) 0.87 0.92
rs8050136 FTO 0.91  (0.70–1.18) 0.46
0.81  
(0.58–1.13) 0.21
1.10  
(0.72–1.67) 0.66 0.23
rs560887† G6PC2 1.11  (0.74–1.66) 0.61
0.78  
(0.44–1.39) 0.40
1.76  
(1.00–3.09) 0.050 0.045
rs1799884 GCK 0.99  (0.76–1.28) 0.92
1.10  
(0.80–1.52) 0.57
0.81  
(0.52–1.26) 0.36 0.39
rs1260326† GCKR 1.36  (1.01–1.82) 0.043
1.24  
(0.84–1.83) 0.28
1.53  
(0.97–2.42) 0.068 0.47
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rs1111875 HHEX 1.00  (0.78–1.27) 0.97
0.92  
(0.67–1.26) 0.61
1.19  
(0.80–1.77) 0.38 0.33
rs7957197 HNF1A (TCF1)
1.17  
(0.92–1.48) 0.20
1.18  
(0.87–1.59) 0.30
1.16  
(0.80–1.70) 0.43 0.89
rs7501939† HNF1B (TCF2)
1.49  
(1.11–2.00) 0.008
1.49  
(1.03–2.17) 0.036
1.49  
(0.91–2.45) 0.11 0.99
rs35767 IGF1 0.87  (0.67–1.12) 0.27
0.78  
(0.56–1.10) 0.16
1.00  
(0.68–1.48) 1.00 0.40
rs4402960 IGF2BP2 0.90  (0.71–1.13) 0.36
0.78  
(0.58–1.06) 0.11
1.10  
(0.76–1.60) 0.60 0.16
rs20541† IL13 1.42  (0.89–2.27) 0.14
0.93  
(0.45–1.90) 0.84
2.38  
(1.24–4.57) 0.009 0.07
rs2943641 IRS1 1.13  (0.89–1.43) 0.33
1.01  
(0.75–1.38) 0.93
1.38  
(0.94–2.02) 0.10 0.30
rs864745 JAZF1 0.90  (0.71–1.15) 0.40
1.01  
(0.73–1.39) 0.98
0.75  
(0.52–1.09) 0.14 0.22
rs5215 KCNJ11 1.09  (0.86–1.37) 0.49
1.39  
(1.02–1.90) 0.038
0.79  
(0.55–1.13) 0.20 0.022
rs5219 KCNJ11 1.11  (0.87–1.43) 0.39
1.37  
(0.98–1.91) 0.063
0.88  
(0.60–1.28) 0.50 0.12
rs2237897 KCNQ1 1.25  (0.88–1.77) 0.21
1.28  
(0.81–2.01) 0.28
1.22  
(0.71–2.10) 0.48 0.83
rs2074196 KCNQ1 1.57  (1.03–2.40) 0.036
1.83  
(1.01–3.32) 0.047
1.42  
(0.77–2.59) 0.26 0.48
rs2237892 KCNQ1 1.38  (0.97–1.97) 0.070
1.53  
(0.97–2.41) 0.065
1.24  
(0.70–2.18) 0.46 0.53
rs2237895 KCNQ1 1.06  (0.82–1.36) 0.66
1.30  
(0.94–1.80) 0.11
0.74  
(0.50–1.11) 0.15 0.033
rs231362 KCNQ1OT1 1.15  (0.88–1.51) 0.31
1.04  
(0.73–1.47) 0.84
1.34  
(0.87–2.07) 0.19 0.33
rs1041981 LTA 0.86  (0.68–1.09) 0.21
0.76  
(0.56–1.04) 0.088
1.04  
(0.71–1.51) 0.85 0.25
rs7944584† MADD 0.68  (0.46–1.01) 0.058
0.55  
(0.32–0.95) 0.031
0.83  
(0.46–1.52) 0.55 0.27
rs12970134 MCR4 0.89  (0.70–1.12) 0.31
0.86  
(0.64–1.16) 0.31
0.94  
(0.65–1.35) 0.74 0.71
rs1387153 MTNR1B 0.89  (0.71–1.12) 0.32
1.01  
(0.75–1.37) 0.93
0.71  
(0.49–1.02) 0.063 0.16
rs10923931 NOTCH2 0.98  (0.73–1.31) 0.88
1.05  
(0.72–1.53) 0.81
0.88  
(0.55–1.41) 0.59 0.58
rs6698181 PKN2 1.17  (0.92–1.48) 0.20
1.28  
(0.94–1.75) 0.12
1.00  
(0.69–1.46) 0.98 0.33
rs1801282 PPARG 0.84  (0.65–1.10) 0.21
0.66  
(0.46–0.96) 0.030
1.12  
(0.76–1.65) 0.56 0.09
rs8042680† PRC1 0.91  (0.64–1.29) 0.60
1.13  
(0.74–1.73) 0.56
0.56  
(0.29–1.07) 0.081 0.08
rs340874 PROX1 1.03  (0.78–1.36) 0.83
0.75  
(0.52–1.07) 0.11
1.60  
(1.02–2.50) 0.041 0.016
rs7593730 RBMS1 0.92  (0.73–1.16) 0.48
0.77  
(0.56–1.05) 0.10
1.20  
(0.83–1.75) 0.33 0.07
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meta-analysis with available GWAS data of the Heidelberg 
population. Although there was a partial overlapping of 
SNPs between both populations that limited our ability 
to validate some potentially interesting gender-associated 
effects on OS, we could confirm the strong association of 
the SLC30A8rs13266634 SNP with OS in men that could not 
be detected in women (per-allele HRMen = 1.32, 95% CI 
1.13-1.54; Supplementary Table S5). This gender-specific 
association remained significant at the experiment-wide 
significance threshold. On the other hand, although it 
was not statistically significant in the analysis of the 
IMMENSE population, the pooled analysis also showed 
that men carrying the BCL11Ars10490072C allele had a poorer 
OS compared with those carrying the wild type genotype 
whereas no effect was seen in women (HRMen = 1.37, 95% 
CI 1.10-1.70). Finally, we observed in the pooled analysis 
that women bearing the PRC1rs8042680A allele or men 
carrying the PROX1rs340874G allele or the MADDrs7944584T/T 
rs1531343 RPSAP52, HMGA2
1.11  
(0.84–1.46) 0.45
1.40  
(1.00–1.97) 0.053
0.76  
(0.46–1.23) 0.26 0.07
rs11920090 SLC2A2 0.88  (0.67–1.14) 0.34
0.87  
(0.62–1.22) 0.41
0.91  
(0.59–1.40) 0.67 0.91
rs13266634∂ SLC30A8 1.24  (1.05–1.47) 0.011
1.42  
(1.14–1.77) 0.002
1.01  
(0.77–1.33) 0.94 0.057
rs7903146 TCF7L2 0.83  (0.66–1.05) 0.12
0.72  
(0.53–0.97) 0.030
1.04  
(0.72–1.50) 0.82 0.13
rs12255372 TCF7L2 0.87  (0.69–1.09) 0.23
0.73  
(0.54–0.98) 0.039
1.14  
(0.79–1.65) 0.49 0.08
rs7578597 THADA 1.18  (0.88–1.58) 0.27
0.97 (0.67–
1.41) 0.88
1.59  
(0.99–2.55) 0.054 0.12
rs896854† TP53INP1 0.76  (0.58–1.00) 0.050
0.74  
(0.52–1.06) 0.10
0.77  
(0.50–1.19) 0.24 0.81
rs7961581 TSPAN8, LGR5
1.09  
(0.87–1.37) 0.47
1.08  
(0.80–1.47) 0.62
1.14  
(0.79–1.63) 0.49 0.77
rs9472138 VEGFA 1.03  (0.82–1.30) 0.80
0.93  
(0.69–1.26) 0.63
1.19  
(0.83–1.71) 0.33 0.32
rs10010131 WFS1 1.00  (0.78–1.28) 0.99
1.15  
(0.81–1.61) 0.44
0.85  
(0.59–1.23) 0.38 0.28
Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; n/s, not specified. 
Estimates were adjusted for age, sex, country of origin and Durie–Salmon stage. P < 0.05 in bold. 
aEstimates calculated according to a dominant model of inheritance.
bEstimates calculated according to a dominant model of inheritance and adjusted for age, region and Durie–Salmon stage.
†Estimates calculated according to a recessive model of inheritance. 
∂Estimates calculated according to an additive model of inheritance. 
Figure 1: Kaplan-Meier plots for the HNF1Brs7501939 SNP in the IMMENSE (A) and Heidelberg (B) populations.
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Table 3: Meta–analysis for the association of T2D–related variants and overall survival (OS) of 
MM patients
IMMENSE (N = 936) GWAS (N = 700) META-ANALYSIS  (N = 1636)
Variant_
dbSNP Gene OR (95% CI)
a Pvalue HR (95% CI)b Pvalue HR (95% CI)c Pvalue
rs2641348 ADAM30 0.94 (0.69–1.28) 0.69 1.12 (0.86–1.45) 0.41 1.04 (0.85–1.27) 0.69
rs4607103† ADAMTS9 1.23 (0.76–2.00) 0.40  0.99 (0.63–1.55)* 0.98  1.10 (0.79–1.52)* 0.59
rs11708067 ADCY5 0.87 (0.68–1.11) 0.25  0.89 (0.71–1.11)* 0.31  0.88 (0.75–1.04)* 0.13
rs10885122 ADRA2A 1.03 (0.79–1.33) 0.83 0.85 (0.65–1.12) 0.24 0.94 (0.78–1.13) 0.52
rs1552224 ARAPI, CENTD2 0.88 (0.68–1.15) 0.35 1.12 (0.89–1.42) 0.34 1.00 (0.79–1.27) 1.00
rs10490072 BCL11A 1.05 (0.83–1.32) 0.70  1.30 (1.04–1.62)* 0.019  1.17 (0.95–1.44)* 0.14
rs12779790 CDC123, CAMK1D 0.86 (0.67–1.11) 0.24 ND ND ND ND
rs7754840 CDKAL1 1.14 (0.90–1.44) 0.27 1.15 (0.92–1.43) 0.22 1.14 (0.98–1.35) 0.10
rs564398† CDKN2A–2B 0.64 (0.42–0.98) 0.042 1.17 (0.88–1.55) 0.29 0.88 (0.49–1.59) 0.68
rs10811661 CDKN2A–2B 0.93 (0.72–1.19) 0.55 ND ND ND ND
rs2383208 CDKN2A–2B 0.94 (0.73–1.21) 0.64 ND ND ND ND
rs4240702 COL5A1 0.88 (0.68–1.15) 0.35 1.12 (0.87–1.44) 0.39 1.00 (0.79–1.26) 0.97
rs11605924 CRY2 0.91 (0.70–1.18) 0.47  1.05 (0.82–1.35)* 0.70  0.98 (0.82–1.18)* 0.83
rs1153188 DCD 1.18 (0.94–1.48) 0.16  0.85 (0.68–1.07)* 0.16  1.00 (0.73–1.38)* 0.99
rs1113132 EXT2 1.02 (0.81–1.28) 0.86 1.01 (0.81–1.26) 0.93 1.02 (0.87–1.19) 0.86
rs174550 FADS1 1.00 (0.79–1.26) 1.00 1.10 (0.88–1.37) 0.39 1.05 (0.90–1.24) 0.54
rs11071657 FAM148B 0.86 (0.68–1.09) 0.22 1.01 (0.81–1.27) 0.91 0.94 (0.80–1.10) 0.42
rs17044137 FLJ39370 1.06 (0.84–1.33) 0.64  1.04 (0.83–1.31)* 0.71  1.05 (0.89–1.23)* 0.56
rs8050136 FTO 0.91 (0.70–1.18) 0.46 1.02 (0.81–1.29) 0.84 0.97 (0.82–1.15) 0.73
rs560887† G6PC2 1.11 (0.74–1.66) 0.61 0.91 (0.61–1.35) 0.63 1.01 (0.77–1.33) 0.94
rs1799884 GCK 0.99 (0.76–1.28) 0.92  1.04 (0.83–1.31)* 0.74  1.02 (0.86–1.21)* 0.84
rs1260326† GCKR 1.36 (1.01–1.82) 0.043 1.10 (0.83–1.47) 0.51 1.22 (0.99–1.50) 0.061
rs1111875 HHEX 1.00 (0.78–1.27) 0.97  1.00 (0.79–1.25)* 0.97  1.00 (0.85–1.18)* 1.00
rs7957197 HNF1A (TCF1) 1.17 (0.92–1.48) 0.20  1.07 (0.85–1.35)* 0.56  1.12 (0.95–1.32)* 0.19
rs7501939† HNF1B (TCF2) 1.49 (1.11–2.00) 0.008 1.40 (1.06–1.84) 0.016 1.44 (1.18–1.76) 0.0001
rs35767 IGF1 0.87 (0.67–1.12) 0.27 1.08 (0.85–1.37) 0.53 0.98 (0.79–1.20) 0.81
rs4402960 IGF2BP2 0.90 (0.71–1.13) 0.36 0.90 (0.72–1.12) 0.34 0.90 (0.77–1.06) 0.20
rs20541† IL13 1.42 (0.89–2.27) 0.14 0.82 (0.48–1.41) 0.47 1.10 (0.64–1.88) 0.73
rs2943641 IRS1 1.13 (0.89–1.43) 0.33 1.08 (0.86–1.36) 0.49 1.10 (0.94–1.30) 0.24
rs864745 JAZF1 0.90 (0.71–1.15) 0.40  1.01 (0.79–1.30)* 0.94  0.95 (0.80–1.13)* 0.58
rs5215 KCNJ11 1.09 (0.86–1.37) 0.49 0.98 (0.78–1.23) 0.85 1.03 (0.88–1.22) 0.70
rs5219 KCNJ11 1.11 (0.87–1.43) 0.39 0.98 (0.78–1.23) 0.85 1.04 (0.88–1.23) 0.67
rs2237897 KCNQ1 1.25 (0.88–1.77) 0.21 ND ND ND ND
rs2074196 KCNQ1 1.57 (1.03–2.40) 0.036 ND ND ND ND
rs2237892 KCNQ1 1.38 (0.97–1.97) 0.070 1.09 (0.80–1.49) 0.59 1.21 (0.96–1.53) 0.11
rs2237895 KCNQ1 1.06 (0.82–1.36) 0.66 0.94 (0.75–1.19) 0.62 0.99 (0.84–1.18) 0.93
rs231362 KCNQ1OT1 1.15 (0.88–1.51) 0.31 1.04 (0.80–1.35) 0.76 1.09 (0.91–1.32) 0.36
rs1041981 LTA 0.86 (0.68–1.09) 0.21 0.95 (0.76–1.18) 0.64 0.91 (0.77–1.07) 0.24
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genotype showed a significantly better OS when compared 
with those patients carrying the corresponding wild type 
allele or genotype (HRWomen = 0.62, 95% CI 0.39–0.98; 
HRMen = 0.74, 95% CI 0.59–0.94 and HRMen = 0.59, 95% 
CI 0.39–0.87; Supplementary Table S5). The regulatory 
characteristics of the rs10490072, rs8042680 and 
rs7944584 SNPs were changes in transcription binding 
motifs for transcription factors involved in tumorigenesis 
and T- and B-cell malignancies. The rs10490072 changed 
sites for HNF4B, Pou2f2 and Pou5f1 whereas the 
rs8042680 altered sites for GR, PAX5 and TAL1. The 
rs7944584 was found to modify regulatory motifs for AP1, 
AP4, IRF and KAP1. Finally, the rs340874 mapped among 
promoter and enhancer histone marks in primary naïve and 
memory forms of helper T cells (CD4
+) and regulatory T 
cells from peripheral blood. 
DISCUSSION
Previous population-based studies have 
demonstrated the impact of GWAS-identified variants 
for T2D on cancer susceptibility [47, 49–52] and patient 
survival [53]. However, despite these important research 
advances, there is still a noticeable lack of information 
regarding the role of T2D-related variants in modulating 
patient survival especially in hematological malignancies. 
In this scenario, we decided to investigate for the first time 
to our knowledge the relationship between 58 genetic 
variants associated with T2D identified by GWAS and OS 
of MM patients. 
The analysis of the IMMENSE consortium 
data revealed a significant association of the intronic 
HNF1Brs7501939 SNP with poor OS. We successfully 
replicated this association in a large and independent 
population recruited by the University Clinic of 
Heidelberg. However, although a positive correlation 
between this variant and eQTL data on PBMCs has been 
reported [54], we failed to find correlation between the 
risk allele and HNF1B mRNA expression levels on plasma 
cells from a large cohort of MM patients. This suggested 
that the effect of this variant on overall survival is not 
mediated by changes in transcriptional activity of the 
rs7944584† MADD 0.68 (0.46–1.01) 0.058  0.83 (0.56–1.24)* 0.37  0.75 (0.57–0.99)* 0.044
rs12970134 MCR4 0.89 (0.70–1.12) 0.31 1.11 (0.89–1.39) 0.34 1.00 (0.80–1.24) 0.98
rs1387153 MTNR1B 0.89 (0.71–1.12) 0.32 1.12 (0.90–1.30) 0.30 1.01 (0.81–1.26) 0.94
rs10923931 NOTCH2 0.98 (0.73–1.31) 0.88  1.10 (0.85–1.44)* 0.48  1.04 (0.86–1.27)* 0.66
rs6698181 PKN2 1.17 (0.92–1.48) 0.20 0.97 (0.78–1.21) 0.77 1.06 (0.88–1.27) 0.54
rs1801282 PPARG 0.84 (0.65–1.10) 0.21  0.90 (0.70–1.16)* 0.41  0.87 (0.73–1.05)* 0.14
rs8042680† PRC1 0.91 (0.64–1.29) 0.60 1.05 (0.75–1.47) 0.77 0.98 (0.77–1.25) 0.87
rs340874 PROX1 1.03 (0.78–1.36) 0.83  0.81 (0.64–1.03)* 0.08  0.90 (0.71–1.14)* 0.40
rs7593730 RBMS1 0.92 (0.73–1.16) 0.48  1.09 (0.87–1.36)* 0.44  1.00 (0.85–1.19)* 0.96
rs1531343 RPSAP52, HMGA2 1.11 (0.84–1.46) 0.45  0.88 (0.66–1.17)* 0.39  0.99 (0.79–1.25)* 0.94
rs11920090 SLC2A2 0.88 (0.67–1.14) 0.34 0.73 (0.56–0.95) 0.022 0.80 (0.66–0.97) 0.020
rs13266634∂ SLC30A8 1.24 (1.05–1.47) 0.011 1.20 (1.02–1.41) 0.025 1.22 (1.09–1.37) 0.001
rs7903146 TCF7L2 0.83 (0.66–1.05) 0.12 0.84 (0.67–1.05) 0.12 0.84 (0.71–0.98) 0.028
rs12255372 TCF7L2 0.87 (0.69–1.09) 0.23 0.83 (0.67–1.04) 0.10 0.85 (0.73–1.00) 0.043
rs7578597 THADA 1.18 (0.88–1.58) 0.27 0.95 (0.73–1.24) 0.72 1.05 (0.85–1.30) 0.66
rs896854† TP53INP1 0.76 (0.58–1.00) 0.050  0.97 (0.75–1.25)* 0.82  0.86 (0.68–1.10)* 0.23
rs7961581 TSPAN8, LGR5 1.09 (0.87–1.37) 0.47 0.92 (0.74–1.14) 0.44 1.00 (0.85–1.18) 0.98
rs9472138 VEGFA 1.03 (0.82–1.30) 0.80 1.10 (0.88–1.37) 0.39 1.07 (0.91–1.25) 0.43
rs10010131 WFS1 1.00 (0.78–1.28) 0.99 1.07 (0.86–1.35) 0.54 1.04 (0.88–1.23) 0.66
Abbreviations: SNP, single nucleotide polymorphism; HR, hazard ratio; CI, confidence interval. ND, not determined.
Estimates were adjusted for age, sex, country of origin and Durie–Salmon stage. P < 0.05 in facebold. 
a Estimates calculated according to a dominant model of inheritance and adjusted for age, gender, region and Durie–Salmon 
stage.
bEstimates calculated according to a dominant model of inheritance and adjusted for age, gender and clinical trial.
cMeta–analyses were performed assuming a random effect model. 
†Estimates calculated according to a recessive model of inheritance. 
∂Estimates calculated according to an additive model of inheritance. 
*Estimates based on imputed genotypes.
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gene. Nonetheless, given that HFN1B contains multiple 
independent SNPs or haplotypes that have been associated 
with HNF1B mRNA expression [55, 56] and methylation 
[57] levels but also with the risk of developing several 
types of cancer [55–57], it seems to be reasonable to 
consider the possibility that other SNPs within this locus 
and showing a stronger association with OS could explain 
better the link between the HNF1B and clinical outcome. 
However, when we analysed imputed common SNPs from 
the GWAS conducted in the Heidelberg cohort, we could 
not find any stronger association signals with OS in the 
region, which suggested that the HNF1Brs7501939 SNP or 
perhaps a rare SNP in LD with it might be responsible 
of the observed effect. Future fine-mapping studies 
encompassing common but also rare variants within or 
near the HNF1B locus are needed to elucidate whether a 
rare variant or haplotype might account for the observed 
effect. 
HNF1B contains 9 exons and expands over 58 
kb on chromosome 17p21 [58, 59]. It encodes for a 
transcription factor that has been associated with multiple 
clinical features including early-onset of T2D [56]. In 
line with this, it has been also suggested that HNF1B 
may induce impaired glucose tolerance and attenuated 
insulin sensitivity in a miRNA-dependent manner [60], 
which might lead to an enhanced insulin secretion and 
the activation of the IGF1 pathway, an important factor 
mediating myeloma cell growth, proliferation and 
cell maturation [27, 59, 61]. Alternatively, it has been 
postulated that HNF1B is able to influence cancer cell 
survival by promoting the activation of NFkB pathway 
or through the inhibition of mitochondria-associated 
apoptotic signals [62]. In support of the tumorogenic 
effect of HFN1B, it has also been reported that it may 
act as an oncogene [63] and that the HNF1B gene is 
amplified in 23% of all cancers and in about 5% of all 
haematological malignancies (http://broadinstitute.org/
tumorscape). On the contrary, it has also been reported 
that HFN1B may act as tumour suppressor gene [56] 
and that its expression may largely vary depending on 
the target tissue. Whereas HNF1B has been found to be 
overexpressed in ovarian clear cell carcinomas [58] and 
prostate [64] or endometrial [65] cancers and its silencing 
induces apoptosis of cancer cells [58], it has been found 
to be down-regulated in serous epithelial ovarian cancer 
[57] and colorectal, gastric and pancreatic cancer cell 
lines [66]. In addition, it has been reported that the down-
regulation of HFN1B gene is associated with progression 
in hepatocarcinoma [67] and poor prognosis in renal [68] 
and prostate [69] cancers. Considering all the above but 
also the fact that the association of the HNF1Brs7501939 
SNP with OS was driven by a non-diabetogenic (T) 
allele that does not affect HNF1B mRNA expression, we 
hypothesize that the effect of this variant to contribute to 
tumour progression in MM might be mediated by a non-
insulin-dependent mechanism. There was a reasonable 
amount of regulatory data for the HNF1Brs7501939 SNP 
that supported evidence of the active role of the HNF1B 
locus. However, whether elevated HNF1B levels lead to 
tumour transformation and disease progression is not yet 
understood and functional studies to examine whether 
HNF1B variants influence cancer prognosis are lacking. 
Another interesting finding of this study was the 
association of the BCL11A, MADD, PRC1, PROX1, 
SCL30A8, SLC2A2 and TCF7L2 SNPs with OS. We 
found an overall association of the SLC2A2rs11920090T 
and TCF7L2rs7903146T alleles with better OS whereas the 
association of the SLC30A8rs13266634T, BCL11Ars10490072C, 
PRC1rs8042680A and PROX1rs340874G alleles or the 
MADDrs7944584T/T genotype with OS was restricted to 
male or female genders. Despite the potential interest of 
the associations observed for these SNPs with OS, only 
the association of the SLC30A8rs13266634 SNP with poor 
OS in men reached significance at experiment-wide 
significance threshold. This result suggested a key role of 
the SLC30A8 locus in the modulation of overall survival. 
However, given the consistency of the overall or gender-
specific associations observed for BCL11A, MADD, PRC1, 
PROX1, SLC2A2 and TCF7L2 SNPs with OS across the 
populations tested and considering that gender-specific 
genetic alterations might influence MM survival [48], we 
suggest that these variants might also exert a modest effect 
to modulate patient survival. 
SCL30A8 gene encodes a zinc transporter 
involved in the control of insulin processing and 
secretion [70]. Although no previous studies have 
reported a link between this locus and MM, there are 
evidences that suggest that zinc transporters might 
contribute to cancinogenesis [71, 72] through a gender-
dependent mechanism [73]. The association of the 
coding SLC30A8rs13266634 SNP with OS was due to a 
non-diabetogenic allele suggesting that, rather than 
modulating glucose homeostasis and insulin secretion 
[74], the effect attributed to the SLC30A8 locus on MM 
survival might be driven by a direct effect of Zinc in 
biological processes such as DNA and RNA stabilization 
[75], binding of protooncogenes to DNA [75–77] and 
the activation of IGF1 [26, 27, 61] or telomerase [78]. 
The SLC30A8rs13266634C allele has been consistently 
associated with decreased rates of Zinc transport activitiy 
and reduced intragranular Zinc levels [79]. However, 
eQTL data on plasma cells from MM patients did not 
reveal correlation between this variant and SLC30A8 
mRNA levels suggesting that, rather than regulating 
gene expression, the T allele affect transporter activity 
in an allele-dose-dependent manner causing increased 
Zinc concentration and thereby promoting unlimited 
proliferation of MM cells, disease progression and poor 
survival. In addition, regulatory data suggest that the 
SLC30A8 locus might play a role in survival through the 
modulation of specific transcription factors implicated in 
tumour promotion and dissemination. 
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As for the HNF1B and SLC30A8 SNPs, the 
association of the BCL11Ars10490072 and MADDrs7944584 
SNPs with OS was determined by non-diabetogenic 
alleles. BCL11A functions as a myeloid and B-cell proto-
oncogen and has been associated with the development 
of B-cell malignancies [80, 81] whereas MADD encodes 
for a MAP-kinase activating cell domain involved in 
the control of physiological cell death through TNF- 
and caspase-dependent apoptosis [82]. In contrast to 
these associations, the association of the TCF7L2rs7903146, 
SLC2A2rs11920090 PRC1rs8042680, and PROX1rs340874 SNPs 
with OS was driven by diabetogenic alleles, which 
suggested that the effect of these variants on OS might be 
explained by their regulatory effect on insulin secretion 
and, consequently, on cell proliferation and tumour cell 
growth. Whereas SLC2A2 encodes a highly efficient 
glucose transport that is expressed in pancreatic cells and 
regulates insulin secretion by modulating entry of glucose 
into the pancreatic cell [83], TCF7L2, PRC1 and PROX1 
are proteins that have been involved in β-cell survival and 
function [84] and in glucose and nonesterified fatty acids 
or branched-chain amino acids metabolism in liver [85, 
86]. Despite these interesting results and the regulatory 
data observed for all these SNPs, the lack of information 
regarding T2D status among MM patients did not allow 
us to ensure that the observed effect of the TCF7L2, 
SLC2A2, PRC1, and PROX1 SNPs on OS could not be 
due to a different distribution of diabetic patients when 
grouping by genotype or gender. 
This study had both strengths and limitations. 
Strengths include the use of relative large discovery and 
replication populations that allowed us to validate the 
most interesting associations. Limitations include lack 
of information regarding the classical genetic prognostic 
factors (chromosomal abnormalities, etc.), T2D status 
and a relatively small statistical power to detect modest 
associations with OS, especially when gender-stratified 
analysis were performed. Another limitation was the 
partial overlapping of genetic information between studies 
and the use of imputed genotypes that did not allow to 
perform a reliable validation of the association observed 
for genetic variants within ADAMTS9, BCL11A, KCNQ1, 
MADD and PROX1 genes with overall survival. 
In conclusion, this study reports the first evidence 
of an association between the HNF1Brs7501939 SNP and 
OS for MM and suggests that the HNF1B locus might, 
likely through a non-insulin-dependent mechanism, 
play an important role in modulating MM prognosis. 
Likewise, this study shows a strong association of the 
SLC30A8rs13266634 SNP with poor OS in men that might, 
at least in part, account for gender differences in OS. 
Additional studies using larger and well-characterized 
populations are needed to further replicate these findings 
but also those involving the BCL11A, MADD, PRC1, 
PROX1, SLC2A2 and TCF7L2 loci on OS.
MATERIALS AND METHODS
Patients, clinical data collection and survival 
endpoint definition
A total of 1420 Caucasian MM patients were 
ascertained through the IMMEnSE consortium. Full 
details of this consortium have been published elsewhere 
[87]. In brief, inclusion criteria were newly diagnosed MM 
with Salmon & Durie stage I, II and III, age 18–90 years 
inclusive and Caucasian origin. DNA was purified from 
blood specimens using the QIAamp DNA Blood Mini 
Kit (Qiagen) and clinicophathological characteristics 
including age, gender, country of origin and disease 
stage (Durie-Salmon) were retrospectively gathered from 
medical records in each participant institution (Table 1). 
Diagnosis of patients with symptomatic MM was carried 
out by hematologists according to the International 
Myeloma Working Group (IMWG) criteria [88, 89]. All 
patients within the IMMENSE consortium for whom 
survival information was available were included in 
the study (936 MM cases, 454 women and 482 men) 
(Table 1). All participants gave their written informed 
consent to participate in the study.
SNP selection and genotyping
Fifty-eight variants were selected based on the GWAS 
for T2D [84, 90–126] and were genotyped in the IMMEnSE 
consortium population (Table 4). We considered only SNPs 
that were replicated in large and independent populations 
or which came up in several GWAS or their meta-analyses. 
Additional criteria were potential functionality and linkage 
disequilibrium (LD) between the reported SNPs. The 
genotyping of the selected polymorphisms was carried out at 
GENYO (Centre for Genomics and Oncological Research: 
Pfizer/University of Granada/Andalusian Regional 
Government, Granada, Spain) using KASPar® assays (LGC 
Genomics, Hoddesdon, UK) according to manufacturer’s 
instructions. For internal quality control, 5% of samples 
were randomly selected and included as duplicates. 
Concordance between the original and the duplicate samples 
for the 58 SNPs was ≥ 99.0% . Call rates for all SNPs were 
≥ 90.0% with the exception of the WFS1rs734312 SNP that was 
excluded from further analyses. 
Replication
For replication purposes, seven hundred MM 
patients (296 women and 404 men) were provided by 
the University Clinic of Heidelberg (Germany). This 
cohort consists of 98 GMMG-HD3 trial patients, 291 
GMMG-HD4 trial patients and 311 patients transplanted 
in Heidelberg but not enrolled in clinical trials (Table 1). 
Ethical approval for these patients and written informed 
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Table 4: Selected type-2 diabetes-related SNPs
Gene name dbSNP rs# Nucleotide substitution
Reference 
allele 
IMMENSE
GWAS-
identified risk 
allele for T2D
Location/Aa 
substitution References
ADAM30 rs2641348 T/C T C L359P [103, 124]
ADAMTS9 rs4607103  T/C1 C C Near gene [84, 104, 124]
ADCY5 rs11708067  T/C2 T T Intronic [96, 111] 
ADRA2A rs10885122 G/T G G Near ADRA2A
[96]
ARAPI, CENTD2 rs1552224 G/T T T Near gene [105, 120]
BCL11A rs10490072 C/T T T Near gene [124]
CDC123, 
CAMK1D rs12779790   A/G
3 A G Near gene [84, 104, 124]
CDKAL1 rs7754840 C/G G C Intronic [95, 97, 113]
CDKN2A-2B rs564398  T/C4 T T Near gene
[84, 95, 104, 113, 
116, 122, 124]CDKN2A-2B rs10811661 T/C T T Near gene
CDKN2A-2B rs2383208 A/G A A Near gene
COL5A1 rs4240702 C/T C n/s Intronic [91]
CRY2 rs11605924 A/C C A Intronic [96]
DCD rs1153188 A/T A A Near gene [124]
EXT2 rs1113132 C/G C C Intronic [97, 114]
FADS1 rs174550 C/T T T Intronic [96]
FAM148B rs11071657 A/G A A Near gene [93, 96]
FLJ39370 rs17044137 A/T T A Near gene [95]
FTO rs8050136 A/C C A Intronic [104, 125, 126]
G6PC2 rs560887 G/A G G Intronic [91, 92, 94, 96, 107]
GCK rs1799884 G/A G A Near gene [91, 92, 94, 96, 107]
GCKR rs1260326  C/T5 C T L445P [91, 96, 111]
HHEX rs1111875 G/A G G Near gene [95, 97, 104, 113, 114, 125, 126]
HMGA2 rs1531343 C/G G C Near gene [105, 120]
HNF1A (TCF1) rs7957197 A/T T T Intronic [105, 120]
HNF1B (TCF2) rs7501939  C/T6 C C Intronic [101, 110]
IGF1 rs35767 C/T C C Near gene [96, 106]
IGF2BP2 rs4402960 G/T G T Intronic [84, 95, 97, 104, 113, 125, 126]
IL13 rs20541  C/T7 C T R144Q [95]
IRS1 rs2943641 C/T C C Near gene [109, 117, 120]
JAZF1 rs864745 A/G A A Intronic [84, 124]
KCNJ11 rs5215  T/C8 T C V337I [95, 98, 104, 113, 
121, 125, 126]KCNJ11 rs5219 C/T C T K23E
KCNQ1 rs2237897 C/T T C Intronic
[118, 119, 122, 123]
KCNQ1 rs2074196  G/T9 G G Intronic
KCNQ1 rs2237892 C/T C C Intronic
KCNQ1 rs2237895 A/C A C Intronic
KCNQ1OT1 rs231362 G/A G G Intronic [105, 118, 120]
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consent of trial patients was also obtained. Clinical 
and survival data were prospectively collected for trial 
patients on case report forms and retrospectively gathered 
from medical records for none-trial patients. Genetic 
information of 53 SNPs (36 genotyped SNPs and 17 
imputed SNPs) was extracted from the GWAS conducted 
in the Heidelberg cohort. After imputation, no information 
was available for 5 SNPs. 
In silico functional analysis 
Haploreg (http://www.broadinstitute.org/mammals/
haploreg/haploreg.php) and ENCODE annotation data 
(https://genome.ucsc.edu/ENCODE/) were used to predict 
the functional role of potentially interesting SNPs. 
LTA rs1041981 A/C A A T60N [102]
MADD rs7944584   A/T10 A A Intronic [96]
MCR4 rs12970134 A/G G A Near gene [93]
MTNR1B rs1387153 C/T C T Near gene [91, 107, 120]
NOTCH2 rs10923931 G/T G T Intronic [104, 124]
PKN2 rs6698181 C/T C T Intergenic [95]
PPARG rs1801282   C/G11 C C P12A [90, 95, 104, 113, 121, 124–126]
PRC1 rs8042680 A/C C A Intronic [105, 120]
PROX1 rs340874   A/G12 A G Promoter [96]
RBMS1 rs7593730 C/T C T Intronic [108]
SLC2A2 rs11920090 A/T A T Intronic [96]
SLC30A8 rs13266634   C/T13 C C R325W [84, 90, 95–97, 104, 113, 114, 125, 126]
TCF7L2 rs7903146   C/T14 C T Intronic [95–97, 99, 104, 
11–115, 125, 126]TCF7L2 rs12255372   G/T15 G T Intronic
THADA rs7578597 T/C T T T1187A [124]
TP53INP1 rs896854 A/G G G Intronic [105, 120]
TSPAN8 rs7961581 C/T T C Near gene [100]
VEGFA rs9472138 C/T C T Near gene [124]
WFS1 rs734312 A/G A n/s H611R [110]
WFS1 rs10010131 A/G G G Intronic [110]
n/s, not specified; Aa, Aminoacid; GWAS, genome-wide association studies; OS, overall survival. 
References are listed in Supplementary Material. Effect allele in bold and underlined. 
 1T/T genotype was associated with poor OS in women with an opposite but not significant effect in men.
 2C allele was associated with better OS in women with no effect in men.
 3G allele was associated with better OS in women with no effect in men.
 4C/C genotype was associated with better OS. No gender-specific effect was observed. 
 5T/T genotype was associated with poor OS. No gender-specific effect was observed.
 6T allele was associated with poor OS. No gender-specific effect was observed.
 7T/T genotype was associated with poor OS in women with an opposite but not significant effect in men.
 8C allele was associated with poor OS in men with an opposite but not significant effect in women. 
 9T allele was associated with poor OS. No gender-specific effect was observed.
10T/T genotype was associated with better OS in men with no significant effect in women.
11G allele was associated with better OS in men with an opposite but not significant effect in women. 
12G allele was associated with poor OS in women with an opposite but not significant effect in men. 
13 The presence of each additional copy of the T allele was associated with poor OS in men with no effect in women (additive 
effect). 
14T allele was associated with better OS in men with no effect in women.
15T allele was associated with better OS in men with an opposite but not significant effect in women.
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eQTL analysis
We also assessed whether selected SNPs correlated 
with mRNA expression levels in a public eQTL 
browser for peripheral blood mononuclear cells (http://
genenetwork.nl/bloodeqtlbrowser/) [54]. Expression 
quantitative trait loci (eQTL) data on malignant plasma 
cells of 658 patients from the University Clinic of 
Heidelberg (Germany) were also available for this study. 
Detailed information on sample collection and clinico-
pathological characteristics of MM patients as well as 
technical details of gene expression analysis have been 
published elsewhere [127]. 
Statistical analysis
We used chi-square tests to assess Hardy–Weinberg 
Equilibrium (HWE) for each SNP among IMMEnSE 
patients. The primary outcome was OS and the endpoint 
was defined as death from any cause. Survival time was 
calculated as the time from MM diagnosis (discovery 
population) or the first stem cell transplantation 
(replication population) until the occurrence of the 
study endpoint, censoring at the date of death or the last 
observed follow-up time. Association with OS defined as 
hazard ratio (HR) was calculated for each SNP using Cox 
regression multivariate analysis adjusted for age, gender, 
country of origin and Durie-Salmon stage (IMMENSE 
cohort) or for age, gender and clinical trial (Heidelberg 
cohort). Association estimates were calculated according to 
dominant, recessive and log-additive models of inheritance 
with the major allele as reference for regression analyses 
(Table 4). We also performed gene-gender interaction 
analyses to determine whether the association between 
SNPs and MM OS was of similar magnitude in men and 
women. Survival function was displayed using the Kaplan-
Meier method [128] and survival differences across 
genotypic groups were analysed using the log-rank test. 
In order to account for multiple comparisons, we 
used the Meff/MeffLi method [129], which calculates the 
effective number of independent genetic markers analysed 
(N = 54) on the basis of the spectral decomposition (SpD) of 
matrices of pairwise LD between SNPs (http://neurogenetics.
qimrberghofer.edu.au/SNPSpDlite). In addition, we also 
considered the number of genetic inheritance models tested 
(dominant, recessive and log-additive). This resulted in a 
study-wide significance threshold of 0.00031 ([0.05/54]/3) 
to keep type I error rate at 5% . 
Finally, in order to confirm significant associations, 
a meta-analysis combining genetic data obtained in the 
IMMENSE population with those extracted from the 
GWAS conducted in the Heidelberg cohort was also 
performed following dominant, recessive and additive 
models of inheritance. The I2 statistic was used to assess 
heterogeneity between both studies and the pooled HR 
was computed using the random-effect model (assuming 
that between-study variation might depend on chance or 
random variation and an individual study effect). Random-
effects models are more conservative than fixed-effects 
models and give rise to wider confidence intervals (CI), 
which ensures the reliability of the results even though 
the data come from studies with a relatively different 
design. All statistics were calculated using SPSS (v.20) 
and STATA (v.12) for MAC. 
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